KIF18A and ovarian carcinoma: Given the potential of KIF18A inhibition in ovarian cancer, we conducted preclinical evaluations of a novel KIF18A inhibitor, ATX020 to assess its activity in various HGSOC cell line models including platinum-resistant and PARPi-resistant cell line models [20].